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Background: Healthcare-associated infections (HCAIs) are a cause of high health and
economic burden in the UK. The number of HCAI research studies funded in the UK, and
the associated amount of investment, has not previously been analysed.
Aim: To assess the level of research funding awarded to UK institutions for HCAI research
and the relationship of funded research to clinical and public health burden of HCAIs.
Methods: Databases and websites were systematically searched for information on how in-
fectious disease research studies were funded for the period 1997e2010. Studies specifically
related to HCAI research were identified and categorized in terms of funding by pathogen,
disease, and by a research and development value chain describing the type of science.
Findings: The overall dataset included 6165 studies (total investment £2.6 billion) of which
£57.7 million was clearly directed towards HCAI research across 297 studies (2.2% of total
spend, 2.1% of total studies). Of the HCAI-related projects, 45 studies had a specific focus on
MRSA (£10.3 million), 14 towards Clostridium difficile (£10.7 million), two towards pneu-
monia (£0.3 million) and 103 studies related to surgical infections (£14.1 million). Mean and
median study fundingwas£194,129 (standarddeviation:£429,723) and£52,684 (interquartile
range: £9,168 to £201,658) respectively. Award size ranged from £108 to £50.0 million.
Conclusions: Research investment for HCAIs has gradually increased in the study period,
but remains low due to the health, economic, and social burden of HCAI. Research for
hospital-acquired pneumonia, behavioural interventions, economic analyses, and research
on emerging pathogens exhibiting antimicrobial resistance remain underfunded.
ª 2014 The Authors. Published by Elsevier Ltd on behalf of the Healthcare Infection So-
ciety. All rights reserved.e CC BY-NC-ND license
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bloodstream infection.1 Similarly, rates of Clostridium difficile
infection have been decreasing year on year in the UK since
2008, though they still number almost 15,000 per year, and
there are global concerns about antimicrobial resistance; for
example, carbapenem-resistant Acinetobacter baumannii is
increasing in prevalence and is notable in particular for its
ability to cause infections in immunocompromised patients.2e4
Norovirus is a common pathogen in hospitals, often causing
outbreaks that require the closures of wards in England and
beyond with consequent significant economic burden.5 Viral
hepatitis may be transmitted by multiple routes and in
numerous different settings, including within the healthcare
setting e one review reported on 33 hepatitis B virus outbreaks
that involved 471 patients, with 16 fatal cases.6 In the UK,
there has also been neonatal mortality associated with out-
breaks of pseudomonas.7
The true economic burden of HCAIs across UK hospitals and
other healthcare providers is difficult to establish e the most
recent estimate published in 2000 suggested that the annual
cost of HCAIs in the UK was approximately £1 billion.8 Antimi-
crobial resistance (AMR) has also led to substantial morbidity,
mortality and financial impact on hospitals and other health-
care institutions. Globally, infection prevention and control
has become a priority for healthcare organizations, and insti-
tutional management of HCAIs is recognized as being critical to
improving quality of care and patient safety.9
In the USA, the total annual costs of HCAIs is thought to be
greater than US$9.8 billion, with surgical site infections
contributing to a third of these costs, and approximately 50% of
the incidence is thought to be preventable.10 The infection
rates for HCAIs vary greatly by country.11 Globally, there is a
high burden of antimicrobial resistance bacteria.12 Healthcare-
associated bloodstream infections and pneumonia have been
shown to greatly increase mortality and the length of stay in
intensive care units.13 Modelling studies have typically been
limited to studying transmission pathways in the UK, USA and
The Netherlands, rather than the health, economic, and soci-
etal cost of HCAIs.14 There are few data on the burden of HCAIs
in low-income countries.15
Between 1997 and 2010, UK research institutions received
around £2.6 billion of public and philanthropic funding for in-
fectious disease research from a variety of national and in-
ternational funding sources.16 In this study, we estimate
research funding awarded to UK institutions specifically for
HCAI research, with temporal trends, and assess the relation-
ship of funded research to clinical and public health burden of
HCAIs.Methods
We analysed all the studies funded in a 14-year period
(1997e2010 inclusive) that were clearly relevant to, or had
specific mention of, healthcare-associated infectious disease.
No private sector (commercial) funding was included in this
analysis as few data are publicly available.
The analysis presented here is a subset of a larger study on
funding of infectious diseases in the UK, and as such the
methods have been described in detail elsewhere, but are
discussed here briefly.16 The overarching dataset was devel-
oped following a detailed and systematic search of all thestudies for infectious disease research from the major sources
of public and charitable funding for infectious disease research
studies, including the Wellcome Trust, Medical Research
Council, and other research councils, UK government de-
partments, European Commission, the Bill and Melinda Gates
Foundation, and other research charities. We developed the
dataset by (a) downloading all data from the funder website
and manually filtering the infectious disease studies; or (b)
searching open access databases on the funder website for
infection-related keyword terms; or (c) contacting the funder
directly and requesting details of their infection studies. Fun-
ders were identified through the authors’ knowledge of the
research and development landscape and searches of the
Internet. M.G.H. performed the majority of data extraction,
with support from J.R.F. Each study was assigned to as many
primary disease categories as appropriate.17 Within each
category, topic-specific subsections (including specific patho-
gen or disease) were documented. Studies were also allocated
to one of four research and development categories: preclini-
cal; phase I, II, or III; product development; and implementa-
tion and operational research (including surveillance,
epidemiology and statistical and modelling projects; for defi-
nitions and examples see ResIn18). Funders were considered
either in their own right, or for convenience; some were
grouped into categories, such as in-house university funding,
research charities, and government departments. In total, 26
funder categories were used. Studies were excluded if: (i) they
were not immediately relevant to infection; (ii) they were
veterinary infectious disease research studies; (iii) they con-
cerned the use of viral vectors to investigate non-
communicable diseases; (iv) they were grants for symposia or
meetings; or (v) they included UK researchers, but with the
funding awarded to and administered through a non-UK insti-
tution. Studies were categorized as HCAI research where there
was specific mention of, or a clear implication of relevance to,
HCAIs in the title or abstract. Unfunded studies were excluded.
Grants awarded in a currency other than pounds sterling were
converted to UK pounds using the mean exchange rate in the
year of the award. All awards were adjusted for inflation and
reported in 2010 UK pounds. Analysis was carried out in
Microsoft Excel and Access (versions 2000 and 2007) and Stata
(version 11).Results
We identified 6165 studies funded within the 14-year study
period and covering all infectious disease research, repre-
senting a total investment of £2.6 billion. There were 297
studies of relevance to HCAI research, comprising in number
2.1% of total infectious disease research projects. These 297
studies were awarded £57.7 million, 2.2% of the total spend,
with a median award of £52,684 (interquartile range: £9,168 to
201,658) and mean award of £194,129 (standard deviation:
£429,723) (Table I). Award size ranged from £108 to £50.0
million.
Of the 297 HCAI projects (Table I), MRSA was the most-
studied pathogen across 45 studies (15.2%), and these
received £10.3 million (17.9%) of investment. There were 14
C. difficile studies (4.7%), which received investment of £10.7
million (18.5%), whereas acinetobacter investment totalled
£0.3 million across four studies, viral hepatitis investment
Table I
Investments in healthcare-associated infection (HCAI) research areas by sum, numbers of studies, median and mean award and top funder
Disease No. of
studies
% of
HCAI
study no.
Total
funding
% of
HCAI
funding
Mean award,
£ (SD)
Median award,
£ (IQR)
Top funder,
millions (%)
HCAI 297 NA £57,656,313 NA 194,129 (429,723) 52,684
(9,168e201,658)
Department of Health,
14.3 (24.9)
Pathogen
MRSA 45 15.2% £10,311,703 17.9% 229,149 (610,810) 50,410
(4,566e155,478)
Medical Research Council,
4.3 (41.9)
Clostridium
difficile
14 4.7% £10,658,337 18.5% 761,309 (1,269,328) 122,202
(5,396e1,176,072)
European Commission,
6.7 (63.1)
Norovirus 1 0.3% £684 0 684 (NA) 684 (NA) NHS Trust (NA)
Acinetobacter 4 1.3% £341,518 0.6% 85,379 (158,998) 7,959
(3,675e167,083)
Medical Research Council,
0.3 (94.8)
Hepatitis 13 4.4% £2,032,137 3.5% 156,318 (118,904) 153,325
(66,747e197,873)
Department of Health,
0.5 (24.9)
Pneumonia 2 0.7% £300,800 0.5% 150,400 (70,372) 150,400
(100,639e200,160)
Wellcome Trust,
0.3 (100%)
Prion 6 2.0% £3,717,911 6.4% 619,651 (398,861) 644,033
(249,122e972,600)
Department of Health,
2.7 (73.8)
Pseudomonas 7 2.4% £1,146,868 2.0% 163,838 (137,562) 253,336
(13,813e254,591)
BBSRC, 1.1 (96.0)
Infection group
Antimicrobial
resistance
71 23.9% £15,578,161 27.0% 219,411 (496,690) 91,602
(11,708e227,408)
Medical Research Council,
4.4 (28.5)
Behavioural 18 6.1% £3,145,060 5.5% 174,725 (244,696) 15,967
(7,888e342,018)
Department of Health,
1.1 (36.4)
Catheter-related 14 4.7% £3,582,006 6.2% 255,859 (430,777) 57,402
(22,900e323,559)
Department of Health,
2.6 (71.7)
Cleaning and
decontamination
17 5.7% £5,012,072 8.7% 294,827 (368,736) 144,918
(32,835e374,646)
Department of Health,
3.4 (68.3)
Diagnostics 27 9.1% £4,342,730 7.5% 160,842 (41,462) 41,462
(4,145e130,218)
Department of Health,
3.2 (74.9)
Economics 12 4.0% £1,481,225 2.6% 123,435 (181,743) 53,584
(25,397e157,767)
Department of Health,
1.0 (69.2)
Enteric 20 6.7% £6,518,628 11.3% 325,931 (677,894) 13,194
(2,798e224,592)
European Commission,
2.5 (37.8)
Geriatrics 3 1.0% £525,251 0.9% 175,084 (40,530) 155,478
(148,084e221,690)
Department of Health,
0.2 (42.2)
Paediatrics 15 5.1% £413,028 0.7% 27,535 (26,572) 15,077
(4,567e44,874)
Charity, 0.3 (74.3)
Respiratory 18 6.1% £2,559,453 4.4% 142,192 (108,175) 155,484
(13,813e231,865)
BBSRC, 1.1 (43.1)
Surgery 103 34.7% £14,145,700 24.5% 137,337 (200,539) 49,895
(7,604e166,156)
Medical Research Council,
3.2 (23.0)
Therapeutics 20 6.7% £2,464,179 4.3% 123,208 (182,963) 71,623
(21,783e141,113)
Medical Research Council,
0.7 (30.9)
Vaccinology 8 2.7% £254,480 0.4% 31,810 (34,307) 23,444
(9,218e40,714)
Charity, 0.1 (57.8)
SD, standard deviation; IQR, interquartile range; MRSA, meticillin-resistant Staphylococcus aureus; NHS, National Health Service; NA, not
applicable; BBSRC, Biotechnology and Biological Sciences Research Council.
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ment totalled £1.1 million across seven studies, and norovirus
specifically as HCAI received only £684 in one small study.
Hospital-acquired pneumonia received investment totalling
£0.3 million across just two studies, and prion research
received £3.7 million across six studies.
By cross-cutting theme (Table I), 71 studies (23.9%) focused
on antimicrobial resistance, with an investment of £15.6million (27.0%), and surgical infections were investigated in 103
studies (34.7%), with an investment of £14.1 million (24.5%).
Studies related to behavioural sciences received £3.1 million
(5.5%) investment across 18 studies (6.1%), whereas catheter-
related research received £3.5 million (6.2%) across 14 (4.7%)
studies e of these studies, six were clearly related to urinary
catheters, four to venous catheters and four were unclear.
There were 17 studies (5.7%) considering cleaning regimens or
M.G. Head et al. / Journal of Hospital Infection 87 (2014) 84e91 87decontamination procedures, receiving £5.0 million (8.7%) of
investment. There were no studies specifically relating to HCAI
and global health, nor were there any studies relating to HCAI
and rotavirus or streptococcal infection.
Overall funding appears to have increased over time
(Figure 1), with an increasing focus on antimicrobial resistance
research.19 Along the research and development value chain
(Table II; Figure 2), preclinical research received £23.5 million
across 97 studies, phase IeIII studies received £1.1 million
across 12 studies, product development research received £6.8
million across 34 studies, and implementation and operational
research received £26.2 million across 154 studies. The UK
Department of Health provided the greatest quantities of in-
vestment in HCAI research (£14.3 million, 24.9%), followed by
the European Commission (Figure 3).Discussion
This study is the first systematic analysis of research funding
for HCAIs in the UK. Over the 14-year study period 1997e2010,
297 studies were identified for HCAIs where public funding had
been awarded to a UK institution. The most-studied pathogen
was MRSA (45 studies, £10.3 million). There was a focus on
surgical infections (103 studies, £14.1 million) and antimicro-
bial resistance (71 studies, £15.6 million). The small median
award of HCAI research studies (and wide interquartile ranges,
difference from the mean and associated standard deviation)
demonstrates that there were numerous relatively small1997
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Figure 1. Sum investment ovegrants, set alongside a few large investments. The UK Depart-
ment of Health was the leading investor in HCAI research. The
total investment (2.1% of the dataset) appears to be relatively
low as compared with research funding awarded to some other
infectious diseases, considering that HCAIs constitute one of
the major complications for patients following hospitalization
or contact with other healthcare providers.16
The increase in preclinical science awards for HCAI
research in the later years of this dataset may reflect the
improvements in laboratory technologies that enable preclin-
ical outputs to be effectively incorporated within a hospital
environment, and thus dovetail with pieces of translational
research that aim to be of direct benefit to patients. The
majority of these studies relates to point-of-care diagnostics
and susceptibility testing.
The UK Chief Medical Officer has described antimicrobial
resistance as a public health emergency, and although
approximately one-quarter of all HCAI funding was related to
antimicrobial resistance research, this only totals £15.6 million
and is relatively poorly funded across all of infectious disease
research within this dataset.19,20 Much of the funding for AMR
research was for MRSA, in a time period when incidence of
MRSA peaked and then fell; given around half the MRSA-related
HCAI studies (albeit less than one-third of the funding) related
to translational research, it is entirely possible that research
had an impact on this decline.1 However, the emergence of
highly resistant Gram-negative bacteria poses a real threat to
patients in both healthcare settings and in the community, and
warrants larger research investment.19,20Implementation
Phase I-III
2004 2005 2006 2007 2008 2009 2010
r time by type of science.
Table II
Investments in healthcare-associated infection (HCAI) research areas by type of science
Disease No. of
studies
Total
funding
Preclinical Phase IeIII Product development Operational
Study
numbers
Funding Study
numbers
Funding Study
numbers
Funding Study
numbers
Funding
HCAI 297 £57,656,313 97 £23,498,978 12 £1,090,842 34 £6,769,284 154 £26,297,279
Pathogen
MRSA 45 £10,311,703 14 £6,115,836 1 £653,912 2 £383,468 28 £3,158,485
Clostridium
difficile
14 £10,658,337 6 £4,481,194 0 £0 0 £0 8 £6,177,144
Norovirus 1 £684 0 £0 0 £0 0 £0 1 £684
Acinetobacter 4 £341,518 4 £341,518 0 £0 0 £0 0 £0
Hepatitis 13 £2,032,137 5 £729,894 0 £0 1 £231,831 7 £1,070,413
Pneumonia 2 £300,800 2 £300,800 0 £0 0 £0 0 £0
Prion 6 £3,717,911 1 £249,122 0 £0 0 £0 5 £3,468,789
Pseudomonas 7 £1,146,868 7 £1,146,868 0 £0 0 £0 0 £0
Infection group
Antimicrobial
resistance
71 £15,578,161 26 £9,072,594 0 £0 7 £886,555 38 £5,619,011
Behavioural 18 £3,145,060 0 £0 0 £0 1 £572,511 17 £2,572,550
Catheter-related 14 £3,582,006 5 £1,207,042 0 £0 3 £2,167,734 6 £207,230
Cleaning and
decontamination
17 £5,012,072 4 £129,594 0 £0 3 £378,370 10 £4,504,107
Diagnostics 27 £4,342,730 12 £1,020,859 0 £0 6 £1,039,782 9 £2,282,088
Economics 12 £1,481,225 0 £0 0 £0 0 £0 12 £1,481,225
Enteric 20 £6,518,628 8 £4,582,107 0 £0 2 £18,623 10 £1,917,897
Geriatrics 3 £525,251 0 £0 0 £0 0 £0 3 £525,251
Paediatrics 15 £413,028 1 £41,462 7 £151,588 1 £56,814 6 £163,164
Respiratory 18 £2,559,453 10 £1,679,532 1 £107,282 1 £6,171 6 £766,468
Surgery 103 £14,145,700 36 £6,868,113 10 £956,900 12 £1,852,062 45 £4,468,623
Therapeutics 20 £2,464,179 4 £1,296,707 2 £167,373 10 £773,573 4 £226,525
Vaccinology 8 £254,480 0 £0 8 £254,480 0 £0 0 £0
MRSA, meticillin-resistant Staphylococcus aureus.
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HCAI typically included studies relating to hand hygiene or
attitudes to specific aspects of infection control (e.g. visitor
compliance with restricted movements around a ward); how-
ever, research investment in this area was very limited. The
evaluation of the UK national CleanYourHands campaign, one
of the largest HCAI research studies, concluded that the
campaign had an important role in reducing the rates of some45.7%
1.7%
11.8%
40.8%
Operational research Preclinical research
Phase I, II, III trialsProduct development
Figure 2. Proportion of investment in healthcare-associated
infection research by type of science.HCAIs; however, there are clear gaps in our knowledge of
positive behavioural change in relation to infection control,
and further research is needed to understand which behav-
ioural interventions are effective in healthcare settings.21
There were few studies related to cleaning and decon-
tamination. The challenges of keeping a healthcare environ-
ment clean are complex, and the definition of ‘clean’ varies
across settings. Spores originating from C. difficile complicate
cleaning regimens and the most effective ways of dealing with
them are not entirely clear e for example, whereas one study
found that altering the cleaning regimen contributed to a
decrease in C. difficile infections, another review did not.22,23
There is a wide range of cleaning products available, and
many have not been assessed against patient outcome and
queries over the toxicity and effectiveness of disinfectants
against detergents.24 The median award (£144,918, as against
£52,684 for all HCAIs) indicates that larger investments were
made for cleaning research, although some of these awards
were for research that explored decontamination in relation
to prions. Implementation of the most effective cleaning
policies are likely to be inexpensive without requiring complex
technologies, and perhaps even a small updated portfolio of
research to build upon the existing published work in this area
might be relatively high impact and cost-effective, and
therefore may be considered by funders and healthcare
institutions.
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Figure 3. Total investment in healthcare-associated infection research 1997e2010 by the major funders. ‘Other’ includes contributions
from a variety of funders, with the majority from the government of Northern Ireland, hospital research and development funding and
Scottish government funding (despite being part of the UK, Northern Ireland and Scotland local governments offer localized funding for
biomedical research). DH, UK Department of Health; MRC, Medical Research Council; BBSRC, Biotechnology and Biological Sciences
Research Council.
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burden of HCAIs, and even the most recent efforts are now
somewhat dated.8 There is a real need for new studies in the
UK to estimate more precisely the economic and societal
burden of HCAIs so that research and healthcare resources can
be appropriately allocated in line with the burden. There are
clear acknowledged complexities in carrying out such studies,
but accurately counting the cost of infection is crucial.9
Infections related to surgery were the most commonly
studied aspect of HCAIs in this dataset. Nearly half of the
funding (around one-third of the studies) was related to
laboratory work in relation to surgery, with the most studied
area being implementation and operational research. Several
of these studies researched the impact of viruses from the
herpes family (in particular the EpsteineBarr virus and
cytomegalovirus).
There was very little research specifically on hospital-
acquired pneumonia, although some of the research reported
here will have an association with pneumonia, such as the
studies looking at staphylococci and pseudomonas. Respiratory
tract infections have been identified as the most common HCAI
in acute hospitals, with ventilator-associated pneumonia
associated with high mortality and increased length of stay in
hospital.25 Thus it would seem prudent to increase investments
that specifically investigate pneumonia. Research into pseu-
domonas infection itself was minimal e although the burden is
likely to be fairly small, outbreaks can be high impact in terms
of neonatal fatalities and subsequent negative media coverage
of the hospital(s) involved.7 Norovirus infections are a source ofhigh disease burden, particularly across the winter months, yet
only one small study that focused on this pathogen in a
healthcare setting was funded.
The research, and the background for the research, into
prion disease with particular reference to CreutzfeldteJakob
disease is somewhat different to other areas. All six studies
were funded in years 1997e2000, with no investments there-
after. These years coincide with the peak of notifications,
declining since then, and the media coverage surrounding ‘mad
cow disease’ was at its most widespread during that period. To
date, there have been 176 notifications in total, and all of these
patients have died, with a peak of 28 deaths in 2000 and five
deaths in 2011. It is suggested that the decline in numbers to
very few new notifications will continue, although a second
‘wave’ cannot be ruled out.26 There may be little appetite
among funders and researchers to invest money and time to
continue significant efforts into researching Creutz-
feldteJakob disease unless there is perceived to be a genuine
threat that an epidemic will emerge.
It is of particular interest that we found no studies specif-
ically relating to HCAIs in a global health context, despite
around one-third of total investment in infectious disease
research being related to global health studies and/or patho-
gens.16 It is difficult to assess associations with other areas of
research that are not directly related to HCAIs, but which
nonetheless have an impact, and this may be the case with
some of the studies that had a focus on important pathogens in
low-income countries but that did not specify an HCAI
component to the work or indicate HCAI transmission. We also
M.G. Head et al. / Journal of Hospital Infection 87 (2014) 84e9190did not specifically search for health systems research, which in
a low-income setting may well have an impact on local inci-
dence of HCAIs.
The study has several limitations, which have been high-
lighted and discussed in detail elsewhere.16 There were few
publicly available data from the pharmaceutical industry.
Hence, there is a data gap in relation to funding of clinical trials
and development of new therapeutics, vaccines, and di-
agnostics, which the pharmaceutical and biotechnology in-
dustries are financing. We rely on the original data being
complete and accurate, and are unable to take into account
distribution of funds from the lead institution to collaborating
partners, nor can we assess quantity of each award given to
overheads or the impact of the introduction of full-economic
costing. Moreover, assigning studies to categories is a subjec-
tive and imperfect processe although we used two researchers
when assigning findings to categories in order to reduce inter-
observer error. Our study focuses on UK-led investments e
we do not know whether similar patterns (e.g. a lack of public
or charitably funded clinical trials, and focus on MRSA and
surgical infections) would also emerge if the analysis were
repeated for other high-income countries. Owing to the large
amount of work involved and lack of funded staff time, it has
not been possible to update the analysis to include award data
up to 2013. Nor did we assess any impact of these investments,
via outputs such as publications or patents.
An environment of more rapid transmission of infectious
diseases across borders, weak health systems and inadequate
surveillance creates an imperative for international collab-
orations to effectively manage and control transmission of in-
fections across borders to increase the availability and
reliability of HCAI-related data and knowledge.27 The Global
Burden of Disease Study illustrates the usefulness of such col-
laborations.28 There is a paucity of information available on
HCAI transmission in low-income settings that have weak
health systems, and this is something that needs to be
addressed urgently with tailored surveillance systems in order
to identify the most pressing priorities and develop suitable
interventions. Further research in these settings on the feasi-
bility and impact of cost-effective interventions e such as
education on handwashing and provision of soap e might also
yield some useful information on behavioural interventions
that could increase the adoption of these interventions.
There is a need for funders of other countries to provide
similarly detailed information of funded studies, in order to
build a global database of research studies for infections
generally and HCAI specifically, in order to identify true
research gaps, reduce unnecessary duplication of research,
pinpoint where there is infrastructure and capacity for specific
types of research requiring technology or skills, and to inform
priority setting globally.
The UK has received significant investments in the area of
HCAI research, albeit less than is warranted by the actual
burden of disease and threat of drug resistance. The Depart-
ment of Health has led the investments in this area, with
support from other funding bodies such as the Medical Research
Council, although the quantities of funding have often been
modest. MRSA and infections related to surgery have been
relatively well studied (within the limits of available funding),
but research for hospital-acquired pneumonia, Gram-negative
organisms, behavioural interventions, cleaning studies, and
economic analyses warrant greater attention from funders andpolicy-makers. Research is also needed for modelling studies to
explore the future threats to the welfare of patients in
healthcare settings, such as from Gram-negative organisms and
antimicrobial resistance.Acknowledgements
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